Moderna received a positive opinion from the European Medicines Agency for mCOMBRIAX, a combined COVID-19 and flu vaccine, recommending marketing authorization for adults aged 50 and above in the EU. This marks the world's first flu-COVID combo vaccine to get such a recommendation and represents the company's fourth vaccine to receive a positive CHMP opinion. This development expands its respiratory vaccine portfolio, though it contrasts with ongoing regulatory scrutiny for similar vaccines in the U.S.